Following July 2026's advisory committee vote on seven compounded peptides, the FDA has scheduled a second Pharmacy Compounding Advisory Committee (PCAC) meeting for a new group of five peptides, expected to take place before the end of February 2027. As with the first round, this is a review and recommendation step, not an approval, but it signals the agency's peptide-compounding review process is continuing rather than concluding with the July vote.
What's Happening
The PCAC advises the FDA on which bulk drug substances, including peptides, are appropriate for pharmacies to legally compound under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounds the FDA places on its "Category 2" list are considered to have safety concerns significant enough that compounding pharmacies should not use them, at least without further review. The July 2026 meeting examined seven peptides in that category; a second meeting, expected by February 2027, will take up five more.
Which Peptides Are Under Review This Time
The five peptides slated for the second panel are GHK-Cu (the injectable form of the copper peptide already familiar from topical skincare use and covered in this site's GHK-Cu guide), Melanotan II (the tanning peptide discussed in this site's Melanotan II guide), cathelicidin (also known as LL-37), dihexa acetate, and PEG-MGF (pegylated mechano growth factor, covered in this site's PEG-MGF guide). LL-37 and dihexa are newer additions to this site's coverage; both are explained in dedicated guides published alongside this article.
How This Follows the July 2026 Vote
The first PCAC meeting, held July 23–24, 2026, addressed BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon, all covered elsewhere on this site. The panel voted to recommend several of those compounds for continued or restored legal compounding, a recommendation this site reported on at the time. That vote did not, by itself, change any peptide's legal status; the FDA still has to act on the recommendation. The scheduling of a second panel for a distinct set of peptides shows the agency is treating this as a multi-phase review of its Category 2 list rather than a single one-time event.
What an Advisory Committee Recommendation Does, and Doesn't, Do
It's worth being precise about what any PCAC vote accomplishes. An advisory committee recommendation is not a rulemaking, an approval, or a change in a compound's legal compounding status. The FDA is not bound by its advisory committees' votes, though the agency has historically followed PCAC recommendations in most cases involving bulk substances. A "yes" vote from the panel would still need to be followed by formal FDA action removing a compound from Category 2 before compounding pharmacies could legally produce it. None of the peptides under review, including those in this round, are FDA-approved drugs; a favorable compounding recommendation would not make them approved medications, would not establish an approved dose, and would not create a standardized safety or efficacy profile the way FDA drug approval does.
What to Watch For
The most useful things to track over the next several months are: whether the FDA formally schedules and confirms the February 2027 meeting date, what safety and efficacy data the agency's briefing documents disclose ahead of that meeting (these documents, released before FDA advisory meetings, are typically the best public source of the agency's own risk assessment), and how the FDA ultimately acts on the July 2026 panel's recommendations, since that will be the clearest signal of how much weight the second panel's votes are likely to carry.
The Bottom Line
A second FDA advisory panel reviewing GHK-Cu, Melanotan II, LL-37, dihexa, and PEG-MGF is a real, scheduled regulatory event, not a change in any of these compounds' current legal or approval status. All five remain outside the FDA-approved drug supply today, and an advisory committee's recommendation, even a favorable one, would not change that on its own.